Mirvetuximab soravtansine
3 abstracts
Abstract
Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine.Org: University Hospital Leuven, Leuven Cancer Institute and BGOG, Department of Medical Oncology, Clínica Universidad de Navarra, Bon Secours Hospital Cork and Cancer Trials Ireland, Heilbronn Women's Clinic, US Oncology Research, Texas Oncology and Gynecologic Oncology Group (GOG) Foundation,
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,